Science

New Hope for Alzheimer's Treatment

Learn Science on mps-science.com. New Hope for Alzheimer's Treatment article will help answer your questions on Science.We at mps-science.com specialize in Science. Science at mps-science.com provides the most up to date news and articles. If you have questions please do not hesitate to contact us.

The focus is on amyloid beta oligomers, a new wrinkle on an older hypothesis called the 'amyloid cascade hypothesis'.

However, in 19982 and in 20023, researchers proposed that it was not the amyloid beta plaques themselves that were neurotoxic - and therefore the cause of Alzheimer's - but rather precursors to amyloid beta plaques formed by smaller aggregates of amyloid beta. The previous attempts, though not successful, did

It is currently estimated that people over 65 years of age have a 10% show up of developing Alzheimer's, while those over 85 have a 50% likelihood of developing AD, making it the leading producer of dementia midst older people. Though the disease is related primarily with memory loss, its effects also comprise a number of other severe disabilities, including changes in personality, disorientation, difficulty with speech and comprehension, and a lack of technical skill to move normally.

Consequently, most Alzheimer's patients require a great deal of care, costing society to $100 a billion annually. chiming to canonical Fritze, Ph.D., Director of the Products Division at Covance Research Products, 'The impact of Alzheimer's Disease on our society will only increase as our population ages. The prevalence of the disease and disabling effects on the patient are significant by themselves. In boost we are lovely to behold increasingly on the job of the far-reaching effects on families, care-giver networks and the economics of our health care system. The drive for progress towards effective treatments by the research and drug development nuclear family is growing stronger every day.'

A New Consensus

But recent developments in the medical research variety do provide some hope. During the last two years, there has been a growing consensus betwixt Alzheimer researchers at random the reason of Alzheimer's disease, providing focus for scientists exploring the new treatment options.

The focus is on amyloid beta oligomers, a new wrinkle on an older hypothesis styled the 'amyloid drop off hypothesis'. Widespread acquiescence of this new conclusion is something of a milestone in the history of Alzheimer's research. As Dr. Fritze says, 'The decades old quest for the originative intendant in Alzheimer's Disease has recently focused on the precursors of amyloid plaques. These precursors are part of a wondrous robe of processed (APP) Amyloid Precursor Protein) variants, Tau isoforms and secretase components that play a role in neuronal cytotoxicity and subsequent internals dysfunction.'

Amyloid plaques are sticky protein deposits in the autonomic nervous system containing amyloid beta peptide. Researchers have accompanying the buildup of this plaque with Alzheimer's disease since its discovery in 1907. But despite the shining correlation, scientists were not sure what, exactly, spurred the onset of Alzheimer's Disease. The hypothesis that amyloid beta congeries in the discursive reason is the major guiding star of Alzheimer's Disease1 has been the focus of much anticipation over the past decade. though this hypothesis was the leading explanation for the draw on of AD, it had several weaknesses. The most obvious problem with the theory was the fact that the buildup of amyloid beta peptides did not necessarily correspond with the severity of Alzheimer's symptoms.

However, in 19982 and in 20023, researchers proposed that it was not the amyloid beta plaques themselves that were neurotoxic - and therefore the use force upon of Alzheimer's - but rather precursors to amyloid beta plaques formed by smaller aggregates of amyloid beta. These new ideas are gaining widespread signature betwixt and between the Alzheimer's research community, creating a consensus that had not existed before.

This new focus provides one more spur to effect for Alzheimer's researchers, and underscores the need for further advancement. 'The AD field demands sophisticated, highly-sensitive research tools to track these components and quantitate the existence of monomeric, oligomeric and fibrillar amyloid forms present in the progression of Alzheimer's disease,' says Dr. Fritze.

Antibody Treatment

Two new studies, both released in October 20044, suggest that new treatment options may be on the horizon. The studies are the modification of one of two previous attempts using amyloid beta (Aβ) antibodies in the treatment of Alzheimer's Disease. The previous attempts, though not successful, did at least suggest new courses of trick in Alzheimer's research and provided invaluable information for researchers.

In the first of the two previous attempts, researchers injected the blood group itself - pieces of the beta amyloid protein that makes up amyloid plaque - into mice, in the hopes that the injections would generate an immune (antibody) response in preparation for amyloid. Results were initially positive. The injected circulation produced Aβ antibodies and slowed the onset of the disease by decreasing Aβ levels. However, when tried on humans, the procedure led to meningoencephalitis (an inflammation of tissue the brain) in some patients, and was therefore halted.

In the second attempt, a passive immunity therapy was tried in which antibodies to amyloid beta (not amyloid protein) were injected into mice, but hemorrhaging and inflammation ensued due to the high antivenin doses required to be effective.

New Hope

But now there appears to be new hope for the use of antibodies as therapeutic agents for the treatment of Alzheimer's patients. In the first of the two new studies that appeared in October conducted by the National Institute for Longevity Sciences, NCGG, and the Center for Neurological Diseases, Brigham & Women's College, Harvard Institute of Medicine, researchers modified the first procedure. Concluding that the meningoenchaphalitis which occurred in some patients was grown by autoimmune T-cell activation, the researchers hoped to develop a vaccine that could minimize this T-cell garrison state while retaining the production of Aß antibodies. To discharge this they created an oral vaccine that close Aß DNA to an adeno-associated virus vector, which served to mitigate T-cell activation. Thus they were able to decrease Aß levels in the nous of the mice and yet not reactivate T-cells to the degree they had before, greatly reducing the risk of meningoencephalitis.

In the other new study, conducted at the University of Illinois at Chicago, researchers succeeded in making the passive immunity protocol much safer. This they experienced by motley the point of entry for the Aß antibodies. Rather than injecting the antibodies into the body of the mice, as was done previously, antitoxin was injected directly into the fell of the mice. as things go the antibodies were injected directly into the brain, smaller doses were needed, and side effects were minimized.

The results of the likewise studies, and the potential for further optimized immunization strategies may prove to be watershed events in the history of Alzheimer's treatment.

Covance is a leading provider of innovative blood group products and custom arterial blood development services to the research complicity for Alzheimer's disease. Visit http://www.Covance.com for more in-depth information and to view the suite of products for Alzheimer's disease. Boris Predovich is Vice President of Immunology and Surgical Services at Covance Research Products.

Notes

1. J.A. Hardy, G.A. Higgins (1992), Science, 256:184-5. 2. M.P. Lambert et al (1998), Proc Natl Acad Sci, 95:6448-53. 3. D.M. Walsh et al (2002), Nature, 416:535-9. 4. Neelima B. Chauhan et al (2004), Journal of Neuroscience Research, 78, 5:732-741. Hideo Hara et al (2004), Journal of Alzheimer's Disease, 6, 5:483-488.

This paper is copyrighted by Covance. It may not be reproduced in whole or in part and may not be posted on other websites without the express written permission of the establish who may be contacted via email at Covance@digitalbrandexpressions.com.


Asthma & Allergy Cure -Drug Free! - Never suffer again with this safe, proven, highly effective asthma & allergy treatment $24.86 + per sale High Conversion rate.
Cure Your Asthma In Just One Week. - Powerful 100% Natural treatment for asthma, sinus & allergies. High conversion & payout for affiliates. $22.61 per sale.


Article Index: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30

More Articles: